06.08.15
According to a recently published report by Vancouver, British Columbia-based iData Research growth of the European total intravenous (IV) set market is solely driven by a slight increase in unit sales as the average selling price of all device types has been decreasing due to fierce competition and sluggish economic conditions. This market includes primary—dedicated and non-dedicated—and secondary IV sets as well as IV extension sets.
According to a recent report by iData Research, in 2014, the intravenous (IV) set market was the fastest growing segment of the European infusion therapy device market valued at nearly $729 million, or 600 million euros.
“The increased occurrence of diseases that demand infusion therapy will lead to an increase in the utilization of installed pumps before promoting an increase in unit sales for capital-intensive devices,” said Kamran Zamanian, Ph.D., CEO of iData. “However, unit sales for secondary IV sets are growing significantly slower than sales of primary IV sets as a result of safety concerns regarding the occurrence of medication error.”
Unit sales of primary IV sets are mainly driven by the increasing age of the European population and corresponding growth of the patient pool. Overall, market growth has been influenced by strong unit sales growth and a high ASP of primary IV sets dedicated to electronic ambulatory pumps. The growth of secondary IV sets is driven by the increasing number of chemotherapy infusions taking place in hospitals. IV extension sets, used to add length to access IV ports are seeing the highest increases in their use in neonatal intensive care units, analysts noted.
Regulating agencies have issued warnings about the potential dangers of constructing IV sets and their accessories out of plastics containing di-2-ethylhexyl phthalate (DEHP). Because of these concerns, the European Commission recommends that manufacturers label their devices as containing DEHP, or consider replacing these devices with non-DEHP alternatives. Newer, non-DEHP tubing sets are sold at a higher price than their conventional counterparts, which is driving the IV set market.
B. Braun is the leading competitor in the European IV set market, with more than 30 percent market share, according to iData.
“They (B. Braun) have a strong presence in the large volume infusion pump markets in Europe, and because the IV sets used with large volume pumps are dedicated, the company derives a great part of its IV set unit sales from the installed base of these pumps,” according to iData.
Other notable competitors in intravenous set market include, Fresenius Kabi, Codan, Hospira, Baxter International, Becton Dickinson and Company, Doran International, ICU Medical, Smiths Medical, and Vygon, among others.
According to a recent report by iData Research, in 2014, the intravenous (IV) set market was the fastest growing segment of the European infusion therapy device market valued at nearly $729 million, or 600 million euros.
“The increased occurrence of diseases that demand infusion therapy will lead to an increase in the utilization of installed pumps before promoting an increase in unit sales for capital-intensive devices,” said Kamran Zamanian, Ph.D., CEO of iData. “However, unit sales for secondary IV sets are growing significantly slower than sales of primary IV sets as a result of safety concerns regarding the occurrence of medication error.”
Unit sales of primary IV sets are mainly driven by the increasing age of the European population and corresponding growth of the patient pool. Overall, market growth has been influenced by strong unit sales growth and a high ASP of primary IV sets dedicated to electronic ambulatory pumps. The growth of secondary IV sets is driven by the increasing number of chemotherapy infusions taking place in hospitals. IV extension sets, used to add length to access IV ports are seeing the highest increases in their use in neonatal intensive care units, analysts noted.
Regulating agencies have issued warnings about the potential dangers of constructing IV sets and their accessories out of plastics containing di-2-ethylhexyl phthalate (DEHP). Because of these concerns, the European Commission recommends that manufacturers label their devices as containing DEHP, or consider replacing these devices with non-DEHP alternatives. Newer, non-DEHP tubing sets are sold at a higher price than their conventional counterparts, which is driving the IV set market.
B. Braun is the leading competitor in the European IV set market, with more than 30 percent market share, according to iData.
“They (B. Braun) have a strong presence in the large volume infusion pump markets in Europe, and because the IV sets used with large volume pumps are dedicated, the company derives a great part of its IV set unit sales from the installed base of these pumps,” according to iData.
Other notable competitors in intravenous set market include, Fresenius Kabi, Codan, Hospira, Baxter International, Becton Dickinson and Company, Doran International, ICU Medical, Smiths Medical, and Vygon, among others.